{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T02:12:20Z","timestamp":1794967940305,"version":"4.9.1"},"reference-count":29,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"22","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>This meta-analysis compared the efficacy and safety of dexamethasone intravitreal implant (DEX) and anti-vascular endothelial growth factor (anti-VEGF) in the treatment of macular edema (ME) secondary to branch retinal vein occlusion (BRVO).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>The PubMed, Embase, Cochrane Library, and Web of Science databases were comprehensively searched for published studies comparing DEX with anti-VEGF for the treatment of ME caused by BRVO. Outcomes of the selected studies included best-corrected visual acuity (BCVA), central macular thickness (CMT), and adverse events. Review Manager (RevMan) 5.3 was used to analyze the data.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Six trials comparing the efficacy and safety of DEX with anti-VEGF were included in this meta-analysis. At 1 month, DEX achieved a mean BCVA superior to that achieved by anti-VEGF (MD\u200a=\u200a\u22120.11, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.0001), in addition to a superior mean BCVA change (MD\u200a=\u200a\u22120.35, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.00001). At 3 months, the mean BCVA showed a significant difference (MD\u200a=\u200a\u22120.06, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.03) between DEX and anti-VEGF treatment, while the mean BCVA change was similar to that with anti-VEGF treatment (MD\u200a=\u200a\u22120.06, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.11). However, neither mean BCVA nor mean BCVA change showed a significant difference between DEX and anti-VEGF treatment at 6 months (MD\u200a=\u200a0.08, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.06; MD\u200a=\u200a0.06, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.43, respectively). Mean CMT and mean CMT change were significantly lower in the DEX group than in the anti-VEGF group at 1 month (MD\u200a=\u200a\u221253.63 \u03bcm, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a&lt;\u200a.00001; MD\u200a=\u200a\u221260.1 \u03bcm, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.005, respectively). However, at 3 months, mean CMT and mean CMT change were similar between DEX and anti-VEGF treatment (MD\u200a=\u200a17.4 \u03bc, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.74; MD\u200a=\u200a18.01 \u03bcm, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.72, respectively). Although mean CMT in the anti-VEGF group was not significantly lower than that in the DEX group at 6 months (MD\u200a=\u200a55.53, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.07), the mean CMT change from baseline achieved by the anti-VEGF treatment was significantly superior to that obtained with DEX (MD\u200a=\u200a75.53, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.0002). Concerning adverse events, no statistically significant differences were observed in the incidence of cataract (OR\u200a=\u200a4.25, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.07), but the use of DEX led to a higher risk of intraocular pressure elevation compared with anti-VEGF treatment (OR\u200a=\u200a12.04, <jats:italic toggle=\"yes\">P<\/jats:italic>\u200a=\u200a.006).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Our results show that visual acuity recovery and CMT were better in the DEX group than in the anti-VEGF group after 1 and 3 months, although the difference in CMT at 3 months was not significant. However, there were no significant differences in terms of visual acuity and CMT between the two groups after 6 months of follow-up. Therefore, DEX may be recommended as the first treatment option in ME associated with BRVO.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000015798","type":"journal-article","created":{"date-parts":[[2019,5,30]],"date-time":"2019-05-30T04:29:42Z","timestamp":1559190582000},"page":"e15798","source":"Crossref","is-referenced-by-count":15,"title":["Comparison of dexamethasone intravitreal implant with intravitreal anti-VEGF injections for the treatment of macular edema secondary to branch retinal vein occlusion"],"prefix":"10.1097","volume":"98","author":[{"given":"Kaibao","family":"Ji","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan Hubei"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Zhang","sequence":"additional","affiliation":[{"name":"Affiliated Eye Hospital of Nanchang University, Nanchang Jiangxi, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Tian","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan Hubei"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqiao","family":"Xing","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Renmin Hospital of Wuhan University, Wuhan Hubei"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20230914","first-page":"133","article-title":"The epidemiology of retinal vein occlusion: the Beaver Dam Eye Study","volume":"98","author":"Klein","year":"2000","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1001\/archopht.126.4.513","article-title":"The 15-year cumulative incidence of retinal vein occlusion: the Beaver Dam Eye Study","volume":"126","author":"Klein","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1080\/02713680701851902","article-title":"Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities","volume":"33","author":"Rehak","year":"2008","journal-title":"Curr Eye Res"},{"key":"R4-20230914","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1097\/IAE.0b013e3182870c15","article-title":"Branch retinal vein occlusion: epidemiology, pathogenesis, risk factors, clinical features, diagnosis, and complications. An update of the literature","volume":"33","author":"Jaulim","year":"2013","journal-title":"Retina"},{"key":"R5-20230914","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.ajo.2005.03.003","article-title":"Pathogenesis of macular edema with branch retinal vein occlusion and intraocular levels of vascular endothelial growth factor and interleukin-6","volume":"140","author":"Noma","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1167\/iovs.14-13961","article-title":"Role of soluble vascular endothelial growth factor receptors-1 and -2, their ligands, and other factors in branch retinal vein occlusion with macular edema","volume":"55","author":"Noma","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/j.ophtha.2010.02.021","article-title":"Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study","volume":"117","author":"Campochiaro","year":"2010","journal-title":"Ophthalmology"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IAE.0b013e318030e77e","article-title":"Intravitreal bevacizumab (Avastin) in the treatment of macular edema secondary to branch retinal vein occlusion","volume":"27","author":"Rabena","year":"2007","journal-title":"Retina"},{"key":"R9-20230914","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/j.ophtha.2014.08.031","article-title":"Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study","volume":"122","author":"Campochiaro","year":"2015","journal-title":"Ophthalmology"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/0301-4738.151460","article-title":"Short-term efficacy of intravitreal triamcinolone acetonide for macular edema secondary to retinal vein occlusion that is refractory to intravitreal bevacizumab","volume":"63","author":"Yoo","year":"2015","journal-title":"Indian J Ophthalmol"},{"key":"R11-20230914","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s12325-011-0019-z","article-title":"The dexamethasone drug delivery system: indications and evidence","volume":"28","author":"London","year":"2011","journal-title":"Adv Ther"},{"key":"R12-20230914","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1016\/j.ophtha.2011.05.014","article-title":"Ozurdex GENEVA Study Group: dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results","volume":"118","author":"Haller","year":"2011","journal-title":"Ophthalmology"},{"key":"R13-20230914","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"R14-20230914","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s10792-017-0618-z","article-title":"A comparison of three different intravitreal treatment modalities of macular edema due to branch retinal vein occlusion","volume":"38","author":"Kaldirim","year":"2018","journal-title":"Int Ophthalmol"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3341\/kjo.2016.0134","article-title":"Bevacizumab versus dexamethasone implant followed by bevacizumab for the treatment of macula edema associated with branch retinal vein occlusion","volume":"32","author":"Moon","year":"2018","journal-title":"Korean J Ophthalmol"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1136\/bjophthalmol-2014-306236","article-title":"Comparison of intravitreal bevacizumab and dexamethasone implant for the treatment of macula oedema associated with branch retinal vein occlusion","volume":"99","author":"Kim","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R20-20230914","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1111\/cxo.12586","article-title":"Low frequency ranibizumab versus dexamethasone implant for macular oedema secondary to branch retinal vein occlusion","volume":"101","author":"Yuksel","year":"2018","journal-title":"Clin Exp Optom"},{"key":"R21-20230914","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1159\/000350812","article-title":"Prospective pilot study: efficacy of intravitreal dexamethasone and bevacizumab injections in the treatment of macular oedema associated with branch retinal vein occlusion","volume":"230","author":"Guignier","year":"2013","journal-title":"Ophthalmologica"},{"key":"R22-20230914","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1111\/aos.13381","article-title":"Head-to-head comparison of ranibizumab PRN versus single-dose dexamethasone for branch retinal vein occlusion (COMRADE-B)","volume":"96","author":"Hattenbach","year":"2018","journal-title":"Acta Ophthalmol"},{"key":"R23-20230914","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1167\/iovs.10-5285","article-title":"Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant","volume":"52","author":"Chang-Lin","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R24-20230914","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s00417-017-3831-6","article-title":"Safety and efficacy of dexamethasone intravitreal implant for treatment of macular edema secondary to retinal vein occlusion in Chinese patients: randomized, sham-controlled, multicenter study","volume":"256","author":"Li","year":"2018","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R25-20230914","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ophtha.2010.03.032","article-title":"Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion","volume":"117","author":"Haller","year":"2010","journal-title":"Ophthalmology"},{"key":"R26-20230914","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1001\/archophthalmol.2009.233","article-title":"A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with standard care to treat vision loss associated with macular edema secondary to branch retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) Study report 6","volume":"127","year":"2009","journal-title":"Arch Ophthalmol"},{"key":"R27-20230914","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00417-016-3431-x","article-title":"Dexamethasone intravitreal implant in retinal vein occlusion: real-life data from a prospective, multicenter clinical trial","volume":"255","author":"Eter","year":"2017","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R28-20230914","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1159\/000368840","article-title":"Retrospective, observational study in patients receiving a dexamethasone intravitreal implant 0.7\u200amg for macular oedema secondary to retinal vein occlusion","volume":"233","author":"Augustin","year":"2015","journal-title":"Ophthalmologica"},{"key":"R29-20230914","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1159\/000342160","article-title":"Repeated intravitreal dexamethasone implant (Ozurdex\u00ae) for retinal vein occlusion","volume":"229","author":"Querques","year":"2013","journal-title":"Ophthalmologica"},{"key":"R30-20230914","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12886-015-0018-y","article-title":"Two or more dexamethasone intravitreal implants as monotherapy or in combination therapy for macular edema in retinal vein occlusion: subgroup analysis of a retrospective chart review study","volume":"15","author":"Singer","year":"2015","journal-title":"BMC Ophthalmol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00005792-201905310-00037","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T21:16:32Z","timestamp":1694726192000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201905310-00037"}},"subtitle":["A meta-analysis"],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":29,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000015798","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5]]}}}